1) Strategy & Leadership - Cardinal Health reported a strong Q3 FY2026, emphasizing the resilience and growth trajectory of its business. - The Pharmaceutical and Specialty Solutions segment remains the primary driver of growth, with a focus on expanding capabilities in Specialty. - The integration of Solaris into the Specialty Alliance is on track, aiming to deliver synergistic benefits. - Cardinal Health is committed to simplifying operations and enhancing supply chain resiliency amidst a dynamic tariff environment.

2) Financial & Segment Results - Total revenue increased by 11% to $61 billion, with gross profit rising 18% to $2.5 billion. - Non-GAAP EPS for Q3 was $3.17, reflecting a 35% increase YoY. - The Pharma segment revenue grew 11% to $56.1 billion, driven by strong demand across various product categories, including a 30% growth in GLP-1s. - Other growth businesses (at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics) saw revenue increase by 31% to $1.7 billion.

3) Problems / Headwinds - The GMPD segment reported flat revenue of $3.1 billion, with a profit decrease to $25 million due to adverse tariff impacts. - The company faces uncertainty regarding tariff refunds, having paid approximately $200 million in tariffs without recognizing any financial impact in Q3. - Changes in the risk profile of the Navista business led to a $184 million pretax goodwill impairment charge, although this does not affect non-GAAP results.

4) Operational or Product Plans - Cardinal Health is focused on enhancing its Specialty business, expecting revenue to exceed $50 billion in FY2026. - The company is investing in technology and infrastructure to improve service levels and operational efficiency. - The integration of ADS into at-Home Solutions is progressing well, with nearly 1,000 new employees and 500,000 new patients onboarded. - Future plans include expanding the Sacramento distribution center to enhance service capabilities on the West Coast.

5) Guidance & Outlook / Investor Angle - Cardinal Health raised its FY2026 non-GAAP EPS guidance to a range of $10.70 to $10.80, reflecting a 30% to 31% annual growth. - The company anticipates continued strong performance in the Specialty segment and is confident in achieving its long-term targets despite potential headwinds from IRA impacts and tariff uncertainties. - The outlook for FY2027 remains positive, with expectations for sustained demand and operational performance.

Bottom line: Cardinal Health's strong Q3 results and raised guidance reflect a resilient business model with robust growth in its Pharmaceutical and Specialty Solutions segment. Despite facing some headwinds, the company's strategic focus on operational efficiency and specialty growth positions it well for long-term value creation.